natgillin/translations-raw huggingface dataset:
In the combined safety database with IMFINZI monotherapy, immune-mediated hypothyroidism occurred in 137 (7.3%) patients, including Grade 3 in 1 (< 0.1%) patient.
V kombinirani podatkovni bazi o varnosti pri samostojnem zdravljenju z zdravilom IMFINZI se je imunsko pogojeni hipotiroidizem pojavil pri 137 (7,3 %) bolnikih, vključno s 3. stopnjo pri 1 (< 0,1 %) bolniku.
IMFINZI 50 mg/mL concentrate for solution for infusion
IMFINZI 50 mg/ml koncentrat za raztopino za infundiranje
IMFINZI was not discontinued in any patient due to hypothyroidism.
Zaradi hipotiroidizma niso zdravila IMFINZI prenehali uporabljati pri nobenem bolniku.
Immune-mediated hypophysitis or hypopituitarism occurred in patients receiving IMFINZI (see section 4.8).
Pri bolnikih, ki so prejemali zdravilo IMFINZI, sta se pojavila imunsko pogojena hipofizitis ali hipopituitarizem (glejte poglavje 4.8).
In the combined safety database with IMFINZI monotherapy, immune-mediated colitis or diarrhoea occurred in 31 (1.6%) patients, including Grade 3 in 6 (0.3%) patients and Grade 4 in 1 (<0.1%) patient.
V kombinirani podatkovni bazi o varnosti pri samostojnem zdravljenju z zdravilom IMFINZI sta se imunsko pogojeni kolitis ali driska pojavila pri 31 (1,6 %) bolnikih, vključno s 3. stopnjo pri 6 (0,3 %) bolnikih in s 4. stopnjo pri 1 (< 0,1 %) bolniku.
It is used when your NSCLC:
Uporablja se, če se vam je nedrobnocelični rak pljuč:
Patients should be monitored for signs and symptoms of colitis or diarrhoea and managed as recommended in section 4.2.
Bolnike je treba spremljati glede znakov in simptomov kolitisa oziroma driske in ukrepati, kot je priporočeno v poglavju 4.2.
In the combined safety database with IMFINZI monotherapy, immune-mediated adrenal insufficiency occurred in 7 (0.4%) patients, including Grade 3 in 1 (< 0.1%) patient.
V kombinirani podatkovni bazi o varnosti pri samostojnem zdravljenju z zdravilom IMFINZI se je imunsko pogojena adrenalna insuficienca pojavila pri 7 (0,4 %) bolnikih, vključno s 3. stopnjo pri 1 (< 0,1 %) bolniku.
Common Musculoskeletal and connective tissue disorders Myalgia
nočno znojenje pogosti Bolezni mišično-skeletnega sistema in vezivnega tkiva mialgija pogosti miozitis občasni polimiozitis redki
Grade 2 or 3 Withhold dose
3. ali 4. stopnja trajno prenehajte uporabljati
Severe infusion related reactions have been reported in patients receiving IMFINZI (see section 4.8).
Pri bolnikih, ki so prejemali zdravilo IMFINZI, so bile opisane hude z infundiranjem povezane reakcije (glejte poglavje 4.8).
How to store IMFINZI
Shranjevanje zdravila IMFINZI
At baseline, no differences in patient reported symptoms, function and HRQoL were observed between IMFINZI and placebo groups.
Izhodiščno med skupino z zdravilom IMFINZI in skupino s placebom ni bilo razlik v simptomih, funkciji ali zdravstveni kakovosti življenja (HRQoL - “health related quality of life”) po navedbi bolnikov.
In the combined safety database with IMFINZI monotherapy, immune-mediated hypopituitarism occurred in 1 (< 0.1%) patient (Grade 3).
V kombinirani podatkovni bazi o varnosti pri samostojnem zdravljenju z zdravilom IMFINZI se je imunsko pogojeni hipopituitarizem pojavil pri 1 (< 0,1 %) bolniku (3. stopnja).
includes abdominal pain, abdominal pain lower, abdominal pain upper and flank pain.
Vključuje bolečine v trebuhu, bolečine v spodnjem delu trebuha, bolečine v zgornjem delu trebuha in bolečine v ledvenem predelu.
Rare Respiratory, thoracic and mediastinal disorders Cough/Productive Cough
Srčne bolezni miokarditis redki Bolezni dihal, prsnega koša in mediastinalnega prostora kašelj/produktiven kašelj zelo pogosti pnevmonitis zelo pogosti disfonija pogosti intersticijska bolezen pljuč občasni
Sixteen of the 31 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day).
16 od 31 bolnikov je prejemalo visokoodmerno zdravljenje s kortikosteroidi (vsaj 40 mg prednizona ali ekvivalenta na dan).
Thirteen of the 19 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day).
13 od 19 bolnikov je prejemalo visokoodmerno zdravljenje s kortikosteroidi (vsaj 40 mg prednizona ali ekvivalenta na dan).
AUTHORISATION
Izrazitost
In the combined safety database with IMFINZI monotherapy, immune-mediated type 1 diabetes mellitus occurred in 1 (< 0.1%) patient (Grade 3).
V kombinirani podatkovni bazi o varnosti pri samostojnem zdravljenju z zdravilom IMFINZI se je imunsko pogojena sladkorna bolezen tipa 1 pojavila pri 1 (< 0,1 %) bolniku (3. stopnja).
Infusion related reactions should be managed as recommended in section 4.2
V primerih z infundiranjem povezanih reakcij je treba ukrepati po priporočilih v poglavju 4.2.
In the combined safety database with IMFINZI monotherapy, immune-mediated nephritis occurred in 3 (0.2%) patients, including Grade 3 in 1 (< 0.1%) patient.
V kombinirani podatkovni bazi o varnosti pri samostojnem zdravljenju z zdravilom IMFINZI se je imunsko pogojeni nefritis pojavil pri 3 (0,2 %) bolnikih, vključno s 3. stopnjo pri 1 (< 0,1 %) bolniku.
Other immune-mediated adverse reactions
Drugi imunsko pogojeni neželeni učinki
• overactive thyroid gland that can cause fast heart rate or weight loss
• prekomerno delovanje žleze ščitnice; posledici sta lahko hitro bitje srca ali hujšanje
Eleven of the 30 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day).
11 od 30 bolnikov je prejemalo visokoodmerno zdravljenje s kortikosteroidi (vsaj 40 mg prednizona ali ekvivalenta na dan).
Grade 2 with ALT or AST > 3-5 x ULN and/or total bilirubin > 1.5-3 x ULN
3. stopnja z AST ali ALT > 5-≤ 8 x ZNM ali celokupni bilirubin > 3-≤ 5 x ZNM
Consider initial dose of 1 mg/kg/day to 4 mg/kg/day prednisone or equivalent followed by taper
3. stopnja odložite uporabo odmerka razmislite o začetnem odmerku od 1 do 4 mg/kg/dan prednizona ali ekvivalenta in nato postopoma zmanjšujte
Hazard ratio (95% CI):
razmerje ogroženosti (95 % IZ):
In the combined safety database with IMFINZI monotherapy, (n = 1889 multiple tumour types), immune-mediated pneumonitis occurred in 79 (4.2%) patients, including Grade 3 in 12 (0.6%) patients, Grade 4 in 1 (< 0.1%) patient, and Grade 5 in 5 (0.3%) patients.
V kombinirani podatkovni bazi o varnosti pri samostojnem zdravljenju z zdravilom IMFINZI (n = 1889, več tipov tumorjev) je do imunsko pogojenega pnevmonitisa prišlo pri 79 bolnikih (4,2 %)
Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper
odložite uporabo odmerka uvedite 1 do 2 mg/kg/dan prednizona ali ekvivalenta in nato postopoma zmanjšujte
Immune-mediated hepatitis, defined as requiring use of systemic corticosteroids and with no clear alternate etiology, occurred in patients receiving IMFINZI (see section 4.8).
Pri bolnikih, ki so prejemali zdravilo IMFINZI, se je pojavil imunsko pogojeni hepatitis, opredeljen kot potreba po sistemskih kortikosteroidih in brez jasne druge etiologije (glejte poglavje 4.8).
• skin rash or itchiness
• kožni izpuščaj ali srbenje
n includes rash erythematous, rash generalised, rash macular, rash maculopapular, rash papular, rash pruritic, rash pustular, erythema, eczema and rash.
Vključuje eritematozen izpuščaj, generaliziran izpuščaj, makularen izpuščaj, makulopapularen izpuščaj, papularen izpuščaj, pruritičen izpuščaj, pustulozen izpuščaj, eritem, ekcem in izpuščaj.
Immune-mediated rash or dermatitis, defined as requiring use of systemic corticosteroids and with no clear alternate etiology, occurred in patients receiving IMFINZI (see section 4.8).
Pri bolnikih, ki so prejemali zdravilo IMFINZI, se je pojavil imunsko pogojeni izpuščaj ali dermatitis, opredeljen kot potreba po sistemskih kortikosteroidih in brez jasne druge etiologije (glejte poglavje 4.8).
Immune-mediated colitis or diarrhoea, defined as requiring use of systemic corticosteroids and with no clear alternate etiology, occurred in patients receiving IMFINZI (see section 4.8).
Pri bolnikih, ki so prejemali zdravilo IMFINZI, sta se pojavila imunsko pogojeni kolitis ali driska, opredeljeno kot potreba po sistemskih kortikosteroidih in brez jasne druge etiologije (glejte poglavje 4.8).
Myositis
Imunogenost
Preparation of solution
Priprava raztopine
Initiate 1 to 4 mg/kg/day prednisone or equivalent followed by a taper
3. ali 4. stopnja trajno prenehajte uporabljati od 1 do 4 mg/kg/dan prednizona ali ekvivalenta in nato postopoma zmanjšujte
Immune-mediated nephritis, defined as requiring use of systemic corticosteroids and with no clear alternate etiology, occurred in patients receiving IMFINZI (see section 4.8).
Pri bolnikih, ki so prejemali zdravilo IMFINZI, se je pojavil imunsko pogojeni nefritis, opredeljen kot potreba po sistemskih kortikosteroidih in brez jasne druge etiologije (glejte poglavje 4.8).
Grade 2
Preglednica 2.
Initiate 2 to 4 mg/kg/day prednisone or equivalent followed by a taper
2. stopnja odložite uporabo odmerka uvedite 2 do 4 mg/kg/dan prednizona ali ekvivalenta in nato postopoma zmanjšujte
Withhold dose
Dajanje zdravila
Posology
Mesec
• underactive thyroid gland that can cause tiredness or weight gain
• premalo dejavna žleza ščitnica; posledici sta lahko utrujenost ali povečanje telesne mase
Severity
• driska
More information about the medicine can be found on the EMA website: ema.europa.eu/medicines/human/EPAR/lartruvo.
Več informacij o zdravilu je na voljo na spletni strani Evropske agencije za zdravila:ema.europa.eu/medicines/human/EPAR/lartruvo.
The review of Lartruvo was initiated on 31 January 2019 at the request of the European Commission, under Article 20 of Regulation (EC) No 726/2004.
Pregled zdravila Lartruvo se je pričel 31. januarja 2019 na zahtevo Evropske komisije v skladu s členom 20 Uredbe (ES) št. 726/2004.
Regarding safety, the data did not show any new safety concerns.
Kar zadeva varnost, podatki niso pokazali nobenih novih varnostnih pomislekov.
In addition, the Agency is preparing a scientific publication on this first revocation of a conditional marketing authorisation.
Agencija bo poleg tega pripravila tudi znanstveno objavo o tej prvi ukinitvi pogojnega dovoljenja za promet.
26 April 2019 EMA/237662/2019 Rev.11
19. julij 2019 EMA/423345/2019
It was approved on condition that the company carried out a study to confirm its benefits.
Odobreno je bilo pod pogojem, da bo podjetje izvedlo študijo, s katero bo potrdilo njegove koristi.
The CHMP opinion will now be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.
Mnenje odbora CHMP je bilo predloženo Evropski komisiji, ki je 19. julija 2019 izdala končni pravno zavezujoči sklep, ki velja za vse države članice EU.
In January 2019, when preliminary results of the ANNOUNCE study became available, the Agency recommended that no new patients should start treatment with the medicine.
Januarja 2019, ko so bili objavljeni predhodni rezultati študije ANNOUNCE, jeagencija priporočila, da se s tem zdravilom ne sme začeti zdraviti novih bolnikov.
• For patients already on treatment with Lartruvo, doctors should consider the available treatment options.
• Pri bolnikih, ki se že zdravijo z zdravilom Lartruvo, morajo zdravniki razmisliti o drugih razpoložljivih možnostih zdravljenja.
Having now assessed the full data from the study, the Agency has concluded that the benefit of Lartruvo in combination with doxorubicin is not confirmed.
Ker je sedaj ocenila celotne podatke iz študije, je zaključila, da korist zdravila Lartruvo v kombinaciji z doksorubicinom ni potrjena.
• There are no new safety concerns with the medicine.
• V zvezi z zdravilom ni nobenih novih varnostnih pomislekov.
• However, that study showed that Lartruvo with doxorubicin is no better than doxorubicin alone at prolonging patients' lives.
• Vendar je ta študija pokazala, da zdravilo Lartruvo v kombinaciji z doksorubicinom ni nič boljše od samega doksorubicina pri podaljševanju življenja bolnikov.
• The phase 3 study ANNOUNCE of Lartruvo in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma did not confirm the clinical benefit of Lartruvo.
• III. faza študije ANNOUNCE z zdravilom Lartruvo v kombinaciji z doksorubicinom pri bolnikih z napredovalim ali metastatskim sarkomom mehkih tkiv ni potrdila kliničnih koristi tega zdravila.
The medicine was therefore granted a conditional marketing authorisation on condition that the company provided additional data from the ANNOUNCE study.
Zdravilo je zato pridobilo pogojno dovoljenje za promet pod pogojem, da podjetje predloži dodatne podatke iz študije ANNOUNCE.
Lartruvo is a cancer medicine that was authorised in the EU on 9 November 2016 to treat adults with advanced soft tissue sarcoma, a type of cancer that affects tissues of the body such as muscles, blood vessels and fat tissue.
Lartruvo je zdravilo za zdravljenje raka, ki je bilo odobreno 9. novembra 2016 za zdravljenje odraslih z napredovalim sarkomom mehkih tkiv, tj. vrste raka, ki prizadene mehka tkiva v telesu, kot so mišice, krvne žile in maščobno tkivo.
• If you are already being treated with Lartruvo, your doctor will consider the most appropriate treatment for you.
• Če se že zdravite s tem zdravilom, bo vaš zdravnik pretehtal najustreznejše zdravljenje za vas.
• The study did not meet its primary objective to prolong survival in the overall population (stratified hazard ratio [HR]: 1.05; median 20.4 for Lartruvo plus doxorubicin versus 19.8 months for placebo plus doxorubicin) or in the leiomyosarcoma sub-population (HR: 0.95; median 21.6 months for Lartruvo plus doxorubicin versus 21.9 months for placebo plus doxorubicin).
• Študija ni izpolnila svojega osnovnega cilja, tj. podaljšanja preživetja v splošni populaciji (stratificirano razmerje tveganja [HR]: 1,05; mediana 20,4 meseca pri jemanju zdravila Lartruvo v kombinaciji z doksorubicinom v primerjavi z 19,8 meseca pri jemanju placeba v kombinaciji z doksorubicinom) ali v podpopulaciji z leiomiosarkomom (HR: 0,95); mediana 21,6 meseca pri jemanju zdravila Lartruvo v kombinaciji z doksorubicinom v primerjavi z 21,9 meseca pri jemanju placeba v kombinaciji z doksorubicinom).
• Additionally, no benefit was shown in terms of prolonging progression-free survival in the overall population (HR: 1.23; median 5.4 months for Lartruvo plus doxorubicin versus 6.8 months for placebo plus doxorubicin), which was one of the secondary objectives of the study.
• Poleg tega niso bile ugotovljene nobene koristi z vidika podaljšanja preživetja brez napredovanja bolezni v splošni populaciji (HR: 1,23; mediana 5,4 meseca pri jemanju zdravila Lartruvo v kombinaciji z doksorubicinom v primerjavi s 6,8 meseca pri jemanju placeba v kombinaciji z doksorubicinom), kar je bil eden od sekundarnih ciljev študije.
Lartruvo was for use together with doxorubicin (another cancer medicine) in patients who could not undergo surgery or radiotherapy (treatment with radiation) and who had not been previously treated with doxorubicin.
Zdravilo Lartruvo se je uporabljalo skupaj z doksorubicinom (drugim zdravilom za zdravljenje raka) pri bolnikih, pri katerih ni bilo mogoče opraviti kirurškega posega ali jih ni bilo mogoče zdraviti z radioterapijo (zdravljenjem z obsevanjem) in ki se predhodno še niso zdravili z doksorubicinom.
The medicine was therefore granted a marketing authorisation on condition that the company provided additional data from the ANNOUNCE study in order to confirm the benefits and safety of the medicine.
Zdravilo je zato pridobilo pogojno dovoljenje za promet pod pogojem, da podjetje predloži dodatne podatke iz študije ANNOUNCE, s katero bi potrdilo koristi in varnost zdravila.
• The marketing authorisation of Lartruvo will therefore be withdrawn and no new patients will be treated with the medicine.
• Dovoljenje za promet z zdravilom Lartruvo bo zato umaknjeno, s tem zdravilom pa se ne bodo zdravili nobeni novi bolniki.
• Lartruvo was approved to treat a rare type of cancer called soft tissue sarcoma.
• Zdravilo Lartruvo je bilo odobreno za zdravljenje redke vrste raka, imenovanega sarkom mehkih tkiv.
EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo
EMA priporoča umik dovoljenja za promet z zdravilom
At the time of its approval, data on the effects of Lartruvo were limited because of the small number of patients included in the main study which supported its authorisation.
V času odobritve zdravila Lartruvo so bili podatki o njegovih učinkih omejeni zaradi majhnega števila bolnikov, vključenih v glavno študijo, ki je bila podlaga za njegovo odobritev.
Lartruvo was to be given in combination with doxorubicin for up to 8 cycles of treatment, followed by Lartruvo alone in patients whose disease has not got worse.
Zdravilo Lartruvo naj bi se dajalo v kombinaciji z doksorubicinom največ osem ciklov zdravljenja, čemur naj bi sledilo samostojno zdravljenje z zdravilom Lartruvo pri bolnikih, pri katerih se bolezen ni poslabšala.
• No new safety concerns were identified during the study.
• Med študijo niso bili ugotovljeni nobeni novi pomisleki glede varnosti zdravila.
The Agency is therefore recommending that the marketing authorisation of the medicine be revoked.
Zato je priporočila ukinitev dovoljenja za promet s tem zdravilom.
Lartruvo was granted a ‘conditional approval'.
Zdravilo Lartruvo je pridobilo pogojno dovoljenje za promet.
• As a consequence, the marketing authorisation of Lartruvo will be revoked and no new patients will be able to receive Lartruvo.
• Zato bo dovoljenje za promet z zdravilom Lartruvo ukinjeno, tega zdravila pa ne bodo mogli prejemati novi bolniki.
Lartruvo was authorised in November 2016 to treat advanced soft tissue sarcoma, a condition for which there is paucity of suitable medicines.
Zdravilo Lartruvo je bilo novembra 2016 odobreno za zdravljenje napredovalega sarkoma mehkih tkiv, tj. obolenja, za katerega je na voljo izredno malo zdravil.
EMA has completed its assessment of the results of the ANNOUNCE study2 and concluded that Lartruvo (olaratumab) with doxorubicin does not prolong the lives of patients with soft tissue cancer more than doxorubicin alone.
Evropska agencija za zdravila (EMA) je 26. aprila 20198 zaključila svojo oceno rezultatov študije ANNOUNCE1 in ugotovila, da zdravilo Lartruvo (olaratumab) v kombinaciji z doksorubicinom nič bolj ne podaljšuje življenja bolnikov z rakom mehkih tkiv kot samostojno jemanje doksorubicina.
Once the European Commission has issued its decision, the Agency will publish on its website the assessment report, with details of the data assessed and the reasons for the revocation.
Poročilo o oceni s podrobnostmi o ocenjenih podatkih in razlogih za ukinitev dovoljenja je na voljo na spletni strani agencije EMA.
18 October 2019
18. oktober 2019
Further information on Translarna's current uses can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/translarna.
Več informacij o trenutnih uporabah zdravila Translarna je na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/translarna.
Does this refusal affect patients in clinical trials?
Ali ta zavrnitev vpliva na bolnike v kliničnih preskušanjih?
What change had the company applied for?
Za katero spremembo je podjetje zaprosilo?
It had issued its initial opinion on 27 June 2019.
Agencija je po zaključku ponovne presoje svoje mnenje izdala 17. oktobra 2019.Svoje prvotno mnenje je izdala 27. junija 2019.
The refusal was confirmed after re-examination.
Ta zavrnitev je bila po ponovni presoji potrjena.
If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.
Če ste vključeni v klinično preskušanje in potrebujete več informacij o zdravljenju, se obrnite na zdravnika, ki sodeluje v kliničnem preskušanju.
What were the main reasons for refusing the change to the marketing authorisation?
Kateri so bili glavni razlogi za zavrnitev vloge za spremembo dovoljenja za promet?
Re-examination confirms refusal
Zavrnitev po ponovni presoji potrjena
The company informed the Agency that there are no consequences for patients who are receiving Translarna in clinical trials.
Podjetje je obvestilo agencijo, da umik nima nobenih posledic za bolnike, ki zdravilo Translarna prejemajo v kliničnih preskušanjih.
Refusal of a change to the marketing authorisation for Translarna (ataluren)
Zavrnitev vloge za spremembo dovoljenja za promet z zdravilom Translarna (ataluren)
Although the main objective of the study was to assess the long-term safety of Translarna, the study also investigated the effectiveness of treatment in patients unable to walk, measuring changes in lung function.
Čeprav je bil glavni cilj študije oceniti dolgoročno varnost zdravila Translarna, so preučevali tudi učinkovitost zdravljenja pri bolnikih, ki ne morejo hoditi, in sicer z merjenjem sprememb v delovanju pljuč.
The additional data from the study could also not confirm the benefit of Translarna in patients no longer able to walk because there were problems with the way data from the CINRG database, which was used to indirectly compare the effects of Translarna, were selected and analysed.
Z dodatnimi podatki iz študije prav tako niso mogli dokazati koristi zdravila Translarna pri bolnikih, ki ne morejo več hoditi, saj so bile težave pri izboru in analizi podatkov iz zbirke podatkov CINRG, ki so jih uporabili za posredno primerjavo učinkov zdravila Translarna.
The company then compared the results with historical data from patients with Duchenne muscular dystrophy recorded in the database of the CINRG (Cooperative International Neuromuscular Research Group).
Podjetje je nato primerjalo rezultate s starimi podatki pri bolnikih z Duchennovo mišično distrofijo iz zbirke podatkov CINRG (kooperativne mednarodne skupine za živčno-mišične raziskave).
Therefore, the Agency was of the opinion that the balance of benefits and risks of Translarna in patients unable to walk could not be established and recommended refusing the change to the marketing authorisation.
Zato je agencija menila, da razmerja med koristmi in tveganji zdravila Translarna pri bolnikih, ki ne morejo več hoditi, ni mogoče določiti, in je priporočila zavrnitev vloge za spremembo dovoljenja za promet z zdravilom.
This is because patients unable to walk are at a more advanced stage of the disease and have reduced muscle mass and therefore the benefits of treatment may be different.
Bolezen pri bolnikih, ki ne morejo hoditi, je namreč v bolj napredovalem stadiju, bolniki pa imajo manjšo mišično maso, zato so koristi zdravljenja lahko drugačne.
The fact that Translarna is handled by the body in a similar way in patients who can walk and those who cannot was not enough to confirm the effectiveness of Translarna in these patients.
Dejstvo, da se zdravilo Translarna pri bolnikih, ki lahko hodijo, in bolnikih, ki ne morejo hoditi, presnavlja podobno, ne zadošča za potrditev učinkovitosti zdravila Translarna pri teh bolnikih.
The company provided data to show that the body handles the medicine in a similar way in patients who are able to walk and those who cannot.
Podjetje je predložilo podatke, ki dokazujejo, da se zdravilo presnavlja podobno pri bolnikih, ki lahko hodijo, in bolnikih, ki ne morejo hoditi.
In addition, the company presented the results of a study involving 94 patients with nonsense mutation Duchenne muscular dystrophy, 44 of whom were no longer able to walk.
Poleg tega je podjetje predložilo rezultate študije, ki je vključevala 94 bolnikov z Duchennovo mišično distrofijo z nesmiselno mutacijo, od katerih jih 44 ne more več hoditi.
There are no consequences for the use of Translarna in its authorised indication.
Zavrnitev vloge nima nobenih posledic za uporabo zdravila Translarna pri odobreni indikaciji.
Patients with Duchenne muscular dystrophy lack normal dystrophin, a protein found in muscles.
Bolnikom z Duchennovo mišično distrofijo primanjkuje normalnega distrofina, tj. beljakovine, ki je prisotna v mišicah.
Translarna has been authorised in the EU since July 2014.
Zdravilo Translarna je v EU odobreno od julija 2014.Vsebuje učinkovino ataluren in je na voljo v obliki zrnc, ki se jemljejo peroralno.